Thomas Björk (Former)
1 – 37 of 37
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Thermodynamic modeling framework for prediction of tool wear and tool protection phenomena in machining
(
- Contribution to journal › Article
- 2015
-
Mark
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations
(
- Contribution to journal › Article
- 2013
-
Mark
Modeling freedom from progression for standard-risk medulloblastoma : A mathematical tumor control model with multiple modes of failure
(
- Contribution to journal › Article
-
Mark
Pituitary disease mortality: is it fiction?
(
- Contribution to journal › Article
-
Mark
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
(
- Contribution to journal › Article
- 2012
-
Mark
A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index.
(
- Contribution to journal › Article
-
Mark
Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma.
(
- Contribution to journal › Article
- 2011
-
Mark
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
(
- Contribution to journal › Article
- 2010
-
Mark
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer : Case-control study
(
- Contribution to journal › Article
- 2008
-
Mark
Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
(
- Contribution to journal › Article
-
Mark
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
(
- Contribution to journal › Article
- 2007
-
Mark
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
(
- Contribution to journal › Article
-
Mark
Prostataspecifikt antigen--den viktigaste cancermarkören. Diagnostik och uppföljning av prostatacancer har förändrats markant.
(
- Contribution to journal › Article
- 2006
-
Mark
Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C.
(
- Contribution to journal › Article
-
Mark
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
(
- Contribution to journal › Article
-
Mark
Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
(
- Contribution to journal › Article
- 2004
-
Mark
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
(
- Contribution to journal › Article
- 2003
-
Mark
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
(
- Contribution to journal › Article
-
Mark
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
(
- Contribution to journal › Article
- 2002
-
Mark
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
(
- Contribution to journal › Article
- 2001
-
Mark
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
(
- Contribution to journal › Article
- 2000
-
Mark
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
(
- Contribution to journal › Article
- 1999
-
Mark
The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
(
- Contribution to journal › Article
-
Mark
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy
(
- Contribution to journal › Article
- 1998
-
Mark
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum
(
- Contribution to journal › Article
-
Mark
Metabolism of free and complexed prostate - specific antigen and their utility for diagnosis and prognosis of prostate cancer
1998)(
- Thesis › Doctoral thesis (compilation)
- 1996
-
Mark
Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues
(
- Contribution to journal › Article
-
Mark
Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
(
- Contribution to journal › Article
- 1995
-
Mark
Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum
(
- Contribution to journal › Article
- 1994
-
Mark
Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia
(
- Contribution to journal › Article
- 1993
-
Mark
Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium
(
- Contribution to journal › Article
-
Mark
Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer
(
- Contribution to journal › Article
- 1989
-
Mark
Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women
(
- Contribution to journal › Article
-
Mark
Use of ciprofloxacin in patients undergoing transurethral prostatic surgery
(
- Contribution to journal › Article
- 1987
-
Mark
Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery
(
- Contribution to journal › Article
- 1986
-
Mark
Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection
(
- Contribution to journal › Letter